A person in Colorado tested positive for avian influenza A(H5N1) virus (H5 bird flu), Colorado Department of Public Health and Environment reported April 28, 2022. Centers for Disease Control and Prevention (CDC) confirmed it is the first U.S. case of H5 bird flu. The person was involved in the culling of poultry with presumptive H5 … 05/05/22 Health Advisory: Colorado person first U.S. case of H5 bird flu
Requested actions Be aware, on April 25, 2022, Centers for Disease Control and Prevention (CDC) issued a Health Alert Network (HAN) advisory about the availability and use of recommended COVID-19 therapies. It also advised against using unproven treatments that have known or potential harm. Follow National Institutes of Health (NIH) COVID-19 treatment guidelines and use … 04/27/22 Health Advisory: CDC Treatment Updates and ACIP discusses eligibility for second booster dose of COVID-19 vaccine
Requested actions Be aware, on March 29, 2022, Food and Drug Administration (FDA) amended its emergency use authorization (EUA) for Moderna COVID-19 booster dose vaccine. A new multi-dose vial is now available. It has a dark blue cap and a label with a purple border. Doses from this vial are 0.5 mL. Multi-dose vials are … 04/08/22 Health Advisory: COVID-19 Information for Providers
Requested actions Be aware, Centers for Disease Control and Prevention (CDC) and Western States Scientific Safety Review Workgroup endorsed Food and Drug Administration’s (FDA’s) emergency use authorization (EUA) of a second booster dose of Pfizer or Moderna COVID-19 vaccines for specific groups. The EUA allows: A second booster dose of Pfizer COVID-19 vaccine at least … 03/30/22 Health Advisory: CDC endorses second booster dose of mRNA COVID-19 vaccine for certain groups
Requested actions Be aware, on March 4, Washington State Department of Health (DOH) discontinued ordering Johnson & Johnson COVID-19 vaccine because inventory is very low at Centers for Disease Control and Prevention (CDC) in Washington Immunization Information System (IIS). We encourage providers to post and look for available doses on IIS vaccine advertisement page. Email … 03/07/22 Health Advisory: Update on Johnson & Johnson vaccine ordering and guidance for healthcare settings
Requested actions Be aware, on Feb. 22, Centers for Disease Control and Prevention (CDC) revised its COVID-19 vaccine clinical considerations. An 8-week interval between first and second doses of mRNA COVID-19 vaccine (Moderna and Pfizer) may be optimal for males 12–39 years old to reduce risk of myocarditis and increase efficacy. CDC still recommends a … 02/25/22 Health Advisory: COVID-19 Updates for Providers
COVID-19 Updates for Providers Requested actions Be aware, on February 11, the Centers for Disease Control and Prevention updated their guidance for COVID-19 vaccination to include: For people who are moderately or severely immunocompromised: People who have completed a primary series of an mRNA vaccine (Pfizer-BioNTech or Moderna) are recommended to receive an mRNA booster … 02/14/22 Health Advisory: CDC Updated Covid-19 Vaccination Guidelines; FDA Postponed its pediatric Covid-19 Vaccination Review
COVID-19 Updates for Providers Requested actions Be aware, U.S. Food and Drug Administration (FDA) granted full authorization to Moderna COVID-19 vaccine for people 18 years or older. Evidence shows the vaccine is safe and effective and manufactured with high quality. The vaccine will now be called Spikevax but has the same formulation as emergency use … 02/01/22 Health Advisory: FDA Provides Full Approval For Spikevax
COVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) endorsed Advisory Committee on Immunization Practices’ (ACIP’s) decision to strongly recommend a single Pfizer COVID-19 vaccine booster dose for people 12–17 years old at least 5 months after their primary series. This expands the age of booster access and strengthens … 01/06/22 Health Advisory: Booster Eligibility Expanded
COVID-19 Updates for Providers Requested actions Be aware, Centers for Disease Control and Prevention (CDC) updated its COVID-19 monoclonal antibody treatment recommendations. Sotrovimab monoclonal antibody formulation retains significant efficacy against Omicron, the dominant circulating variant. Other monoclonal antibody formulations under emergency use authorization (EUA)—bamlanivimab and etesevimab and casirivimab and imdevimab—lack clinical benefit against Omicron and … 01/04/22 Health Advisory: CDC updated antiviral guidance
